BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

PHARNEXT 

Pepiniere Sante Cochin
29 rue du Faubourg Saint Jacques
Paris    75014  France
Phone: 01-55-426200 Fax: 01-55-426201


SEARCH JOBS










 Company News
PHARNEXT And The Hereditary Neuropathy Foundation Collaborate To Increase Awareness Of Charcot-Marie-Tooth Disease 9/16/2014 8:16:15 AM
Ipsen (IPN.PA) Joins PHARNEXT's Board Of Directors 6/30/2014 9:23:00 AM
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014 6:17:34 AM
PHARNEXT Raises an Additional €8 Million for Its PleotherapyTM Platform Applied to the Treatment of Charcot-Marie Tooth Disease and Alzheimer's Disease 2/9/2012 6:50:15 AM
PHARNEXT Has Completed Patient Recruitment for Its Phase II Clinical Trial of PXT3003 (the Company's First Pleodrug™) in Charcot-Marie-Tooth Disease 11/22/2011 10:42:23 AM
PHARNEXT Announces a €2.5 Million Round of Financing 9/8/2011 6:48:38 AM
PHARNEXT Receives Clinical Trial Authorization for a Phase II Study with the First Drug Generated by Its Pleotherapy(TM) Technology 12/3/2010 8:50:25 AM
OSEO Awards a €10.4 Million Funding Package to PHARNEXT, BioSystems International, Bordeaux Hospital (CMRR1), University Bordeaux Segalen and INSERM 11/18/2010 2:09:43 PM
PHARNEXT Raises Eur 4.8 Million Series A Funding 6/9/2010 6:57:32 AM
Ipsen and PHARNEXT Conclude an Exclusive Research, Development and Marketing Agreement 6/15/2009 10:03:31 AM